Dr. Don A. Stevens, MD

Dr. Stevens practices at Norton Women's and Children's Hospital-Operating Room - HOPD in Louisville, Kentucky.

Dr. Stevens' NPI, 1952369621, was assigned on May 3, 2006. Dr. Stevens graduated from University of Louisville School of Medicine in 1982. Dr. Stevens holds Kentucky license 22515.

Dr. Stevens' primary practice is Norton Women's and Children's Hospital-Operating Room - HOPD, at 4001 Dutchmans Ln, Louisville, KY 40207.

Dr. Stevens' primary practice is Norton Women's and Children's Hospital-Operating Room - HOPD in Louisville, Kentucky. Dr. Stevens is also affiliated with Norton Hospital. The medical group on file is Norton Cancer Institute. Dmand AI also links Dr. Stevens to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Stevens practices, 7 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Stevens' primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Stevens is licensed in Kentucky.

CMS data shows 2,104 Medicare services from Dr. Stevens across 12 procedure codes in 2024, for 512 Medicare patients. Medicare paid $156,155 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 512 Medicare patients who saw Dr. Stevens in 2024. The largest group is 65 to 74, with 244 patients. 73% of them have high blood pressure, and 73% have high cholesterol. 7% are also on Medicaid. Their average risk score is 2.07, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Stevens' median patient age at 73, with 53% women.

In 2024, Dr. Stevens wrote 2,454 Medicare Part D claims for 309 patients. 76% of them were for generic drugs. CMS names the drug for 2,138 of them, across 47 drugs with 11 or more claims each, at $6,094,436 in total drug cost. In 2023, CMS named 1,736 claims across 42 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Stevens for performance year 2024, reported as part of a group. Dr. Stevens accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 61 papers to Dr. Stevens, published from 2011 to 2025. 2021 was the busiest year, with 13. The most frequent topics are Oncorhynchus mykiss, Antineoplastic Combined Chemotherapy Protocols and Reactive Oxygen Species. Dr. Stevens has published most often in Aquat Toxicol. Dr. Stevens' most frequent co-authors are Courtney Denton Dinardo, MD, Sundar Jagannath, MD and Moshe Yair Levy, MD.

Dmand AI links Dr. Stevens to 11 clinical trials, 4 of them phase 2 studies. 7 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse and Lymphoma, B-Cell. Open Payments lists research payments to Dr. Stevens that name 4 trials.

CMS Open Payments shows 78 general payments to Dr. Stevens from 28 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 74% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $20,170. It also lists 38 research payments totaling $395,699 from 2017 to 2025, naming 4 clinical trials.

Dr. Stevens graduated from University of Louisville School of Medicine in 1982.